B-MoGen, founded in 2016, develops more complex gene editing tools for use in a wide variety of academic and industry settings.
Being acquired by Bio-Techne will enable B-MoGen to commercialize its products more quickly and efficiently.
“We are delighted with this transaction and we are pleased to have found a local home for our products and technology,” says B-MoGen CEO and president Jeff Liter. “The broad array of products, along with additional marketing and commercial resources, will serve our customers more efficiently and allow our products to be available on a global scale."
B-MoGen was founded four years ago by University of Minnesota researchers David Largaespada, Branden Moriarity and Beau Webber. The company currently has a small staff of about 20 employees.
Read the full story in Twin Cities Business.